Literature DB >> 16245219

A new marker for lipid peroxidation: serum paraoxonase activity in non-alcoholic steatohepatitis.

Mevlüt Başkol1, Gülden Başkol, Kemal Deniz, Omer Ozbakir, Mehmet Yücesoy.   

Abstract

BACKGROUND/AIMS: Relationship between hepatic antioxidant paraoxonase 1 (PON1) activity, lipid peroxidation and liver injury was investigated in patients with non-alcoholic steatohepatitis.
METHODS: A total of 23 patients with non-alcoholic steatohepatitis (15 males, 8 females; mean age: 40.30+/-7.67 yrs) and 23 healthy controls (14 males, 9 females; mean age: 39.70+/- 8.78 yrs) were enrolled in the study. Serum paraoxonase 1 activity and levels of a well-known lipid peroxidation marker, serum malondialdehyde, were determined.
RESULTS: Serum paraoxonase 1 activity decreased significantly in non-alcoholic steatohepatitis compared to the control group (p<0.01). Serum malondialdehyde levels were significantly higher in patients with non-alcoholic steatohepatitis as compared with the control group (p<0.05). No statistically significant correlations were found between serum paraoxonase 1 activities and the grade-stage of non-alcoholic steatohepatitis, serum lipid levels or serum malondialdehyde levels (p>0.05).
CONCLUSIONS: Increased lipid peroxidation may be either a cause or a result of liver injury in patients with non-alcoholic steatohepatitis. Although serum paraoxonase 1 activity does not reflect the degree of liver damage in non-alcoholic steatohepatitis, reduced paraoxonase 1 activity, especially in the presence of mild disease, could be interpreted as a biochemical marker of the lipid peroxidation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16245219

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.852


  7 in total

1.  Noninvasive Diagnosis of NASH and Liver Fibrosis Within the Spectrum of NAFLD.

Authors:  Naim Alkhouri; Arthur J McCullough
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-10

2.  OxNASH score correlates with histologic features and severity of nonalcoholic fatty liver disease.

Authors:  Naim Alkhouri; Michael Berk; Lisa Yerian; Rocio Lopez; Yoon-Mi Chung; Renliang Zhang; Thomas M McIntyre; Ariel E Feldstein; Stanley L Hazen
Journal:  Dig Dis Sci       Date:  2014-01-25       Impact factor: 3.199

3.  Serum Basal Paraoxonase 1 Activity as an Additional Liver Function Test for the Evaluation of Patients with Chronic Hepatitis.

Authors:  Anand K Pyati; Chandrakanth K Halappa; Sudharani A Pyati; Vinod Wali
Journal:  J Clin Diagn Res       Date:  2015-11-01

4.  Paraoxonase activity and expression is modulated by therapeutics in experimental rat nonalcoholic Fatty liver disease.

Authors:  O Hussein; J Zidan; K Abu Jabal; I Shams; S Szvalb; M Grozovski; I Bersudsky; R Karry; M Aviram
Journal:  Int J Hepatol       Date:  2012-03-27

5.  Effect of PON1 gene polymorphisms in Turkish patients with hepatocellular carcinoma.

Authors:  Hikmet Akkız; Sedef Kuran; Ersin Akgöllü; Oğuz Üsküdar; Aynur Bekar; Süleyman Bayram; Selçuk Yıldırım; Yakup Ülger; Berrin Yalınbaş Kaya; Mahmut Şansal; Ercan Çınar
Journal:  Meta Gene       Date:  2013-10-28

6.  Paraoxonase-1 Serum Concentration and PON1 Gene Polymorphisms: Relationship with Non-Alcoholic Fatty Liver Disease.

Authors:  Mircea Vasile Milaciu; Ștefan Cristian Vesa; Ioana Corina Bocșan; Lorena Ciumărnean; Dorel Sâmpelean; Vasile Negrean; Raluca Maria Pop; Daniela Maria Matei; Sergiu Pașca; Andreea Liana Răchișan; Anca Dana Buzoianu; Monica Acalovschi
Journal:  J Clin Med       Date:  2019-12-13       Impact factor: 4.241

7.  Paraoxonase 1 and Non-Alcoholic Fatty Liver Disease: A Meta-Analysis.

Authors:  Kazuhiko Kotani; Jun Watanabe; Kouichi Miura; Alejandro Gugliucci
Journal:  Molecules       Date:  2021-04-16       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.